Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2005-08-16
2005-08-16
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S457000, C514S167000, C530S307000, C530S351000
Reexamination Certificate
active
06929797
ABSTRACT:
The present invention is directed to a conjugate which includes at least one vitamin D moiety thereof and at least one targeting molecule moiety to pharmaceutical compositions of the conjugate, and to methods for using the conjugate for target-specific delivery of vitamin D or analogs thereof to tissues in need thereof. When a particularly preferred form is administered to a patient, the targeting molecule component of the conjugate of this invention seeks out and binds to a tissue of interest, such as bone or tumor tissue, where the vitamin D has a therapeutic effect.
REFERENCES:
patent: 2383446 (1945-06-01), Calcott et al.
patent: 3697559 (1972-10-01), DeLuca et al.
patent: 3741996 (1973-06-01), DeLuca et al.
patent: 3907843 (1975-09-01), DeLuca et al.
patent: 4160803 (1979-07-01), Potts
patent: 4195027 (1980-03-01), DeLuca et al.
patent: 4202829 (1980-05-01), DeLuca et al.
patent: 4225596 (1980-09-01), DeLuca
patent: 4234495 (1980-11-01), DeLuca et al.
patent: 4260549 (1981-04-01), DeLuca et al.
patent: 4292250 (1981-09-01), DeLuca et al.
patent: 4362710 (1982-12-01), Watanabe
patent: 4391802 (1983-07-01), Suda et al.
patent: 4508651 (1985-04-01), Baggiolini et al.
patent: 4554106 (1985-11-01), DeLuca et al.
patent: 4555364 (1985-11-01), DeLuca et al.
patent: 4588716 (1986-05-01), DeLuca et al.
patent: 4661294 (1987-04-01), Holick et al.
patent: 4689180 (1987-08-01), DeLuca et al.
patent: 4698328 (1987-10-01), Neer et al.
patent: 4717721 (1988-01-01), DeLuca et al.
patent: 4833125 (1989-05-01), Neer et al.
patent: 4866048 (1989-09-01), Calverley et al.
patent: 4902481 (1990-02-01), Clark et al.
patent: 5063221 (1991-11-01), Nishii et al.
patent: 5104864 (1992-04-01), DeLuca et al.
patent: 5141719 (1992-08-01), Fernwood et al.
patent: 5157135 (1992-10-01), Tsuji et al.
patent: 5183815 (1993-02-01), Saari et al.
patent: 5205989 (1993-04-01), Aysta
patent: 5219528 (1993-06-01), Clark
patent: 5232836 (1993-08-01), Bouillon et al.
patent: 5264184 (1993-11-01), Aysta et al.
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5334740 (1994-08-01), Takahashi et al.
patent: 5338532 (1994-08-01), Tomalia et al.
patent: 5372996 (1994-12-01), Labrie
patent: 5403831 (1995-04-01), DeLuca et al.
patent: 5417923 (1995-05-01), Bojanic et al.
patent: 5488120 (1996-01-01), Knutson et al.
patent: 5527524 (1996-06-01), Tomalia et al.
patent: 5554386 (1996-09-01), Groman et al.
patent: 5576309 (1996-11-01), Tamura et al.
patent: 5597575 (1997-01-01), Breitbarth
patent: 5602116 (1997-02-01), Knutson et al.
patent: 5614513 (1997-03-01), Knutson et al.
patent: 5637742 (1997-06-01), Valles et al.
patent: 5661025 (1997-08-01), Szoka, Jr. et al.
patent: 5691328 (1997-11-01), Peterson et al.
patent: 5739271 (1998-04-01), Sridhar et al.
patent: 5795882 (1998-08-01), Bishop et al.
patent: 6309666 (2001-10-01), Hatano et al.
patent: 6521608 (2003-02-01), Henner et al.
patent: 6537982 (2003-03-01), Bishop et al.
patent: 877 356 (1979-10-01), None
patent: 0197514 (1986-10-01), None
patent: 0390097 (1990-10-01), None
patent: 0503630 (1992-09-01), None
patent: 0512-844 (1992-11-01), None
patent: 0201-057 (1992-12-01), None
patent: 0562497 (1993-09-01), None
patent: 0664287 (1995-07-01), None
patent: 62000033 (1986-10-01), None
patent: 2-104593 (1990-04-01), None
patent: 5320127 (1993-09-01), None
patent: 6025039 (1994-02-01), None
patent: WO 84/04527 (1984-11-01), None
patent: WO 87/00834 (1987-02-01), None
patent: WO 90/10620 (1990-09-01), None
patent: WO 92/05130 (1992-04-01), None
patent: WO 92/12165 (1992-07-01), None
patent: WO 92/14493 (1992-09-01), None
patent: WO 92/21355 (1992-12-01), None
patent: WO 93/07883 (1993-04-01), None
patent: WO 93/14763 (1993-08-01), None
patent: WO 94/16711 (1994-08-01), None
patent: WO 96/40153 (1996-12-01), None
patent: WO 99/49870 (1999-10-01), None
Stryer et al, in Biochemistry, Third Edition, W. H. Freeman and Company, New York, pp. 569-570, 1988.
Orme et al, Bioorg Med Chem Lett 4: 1375-1380, 1994.
Bauss et al., Effect of 17beta-estraciol-bisphosphonate conugates, potential bone-seeking estrogen pro-drugs, on 17beta-estradiol serum kinetics and bone mass in rats, Sep. 1996, Calcif Tissue Int 59(3): 168-73.
Kobayashi et al, Jan. 1997, Anal Biochem 244(2):374-83.
Holick, M., et al., “Identification of 1,25-Dihydroxycholecalciferol, a Form of Vitamin D3Metabolically Active in the Intestine”,Proc. Natl. Acad. Sci. USA, 68:803-804 (1971).
Holick, M., et al., “1α-Hydroxy Derivative of Vitamin D3: A Highly Potent Analog of 1α,25-Dihydroxyvitamin D3”,Science180:190-191 (1973).
Jensen, G., et al., “Treatment of Post Menopausal Osteoporosis, A Controlled Therapeutic Trial Comparing Oestrogen/Gestagen, 1,25-Dihydroxy-Vitamin D3and Calcium”Clin. Endocrinol.16:515-524 (1982).
Jones, G. et al., “Isolation and Identification of 1,25-Dihydroxyvitamin D2”,Biochemistry, 14:1250-1256 (1975).
Köhler, G., et al., “Continuous Cultures of Fused Cells Secreting Antibody Of Predefined Specificity”,Nature256:495-497 (1975).
Köhler, G., et al. “Derivation of Specific Antibody-Producing Tissue Culture And Tumor Lines by Cell Fusion”,Eur. J. Immunol.6:511-519. (1976).
Lam, H., et al., “1α-Hydroxyvitamin D2: A Potent Synthetic Analog of Vitamin D2”,Science486:1038-1040 (1974).
Miller, G., et al., The Human Prostatic Carcinoma Cell Line LNCaP Expresses Biologically Active, Specific Receptors for 1α,25-Dihydroxyvitamin D3,Cancer Res.52:515-520 (1992).
Orimo, H., et al., “Reduced Occurrence of Vertebral Crush Fractures in Senile Osteoporosis Treated with 1α(OH)-vitamin D3”,Bone and Mineral3:47-52 (1987).
Ott, S., and Chesnut, C., “Calcitriol Treatment in Not Effective in Postmenopausal Osteoporisis”,Ann. Int. Med.110:267-274 (1989).
Ponpipom, M., et al., “Saccharide Receptor-Mediated Drug Delivery”,Receptor-Mediated Targeting of Drugs, (Gregoriadis et al, ed.) NATO ASI series, 53-71 (1983).
Poznansky, M., et al., “Biological Approaches to the Controlled Delivery of Drugs: A Critical Review”,Pharmacol. Rev.36:277-336 (1984).
Molecular Cloning, 2nd ed., Sambrook et al., eds., Cold Spring Harbor Lab. Press, 18.3 et seq. (1989).
Shiraki, M., et al., “Long-Term Treatment of Postmenopausal Osteoporosis with Active Vitamin D3, 1-Alpha-Hydroxycholecalciferol (1α-OHD3) and 1,24 Dihydroxycholecalciferol (1,24(OH)2)D3)”,Endocrinol. Japan32:305-315 (1985).
Skowronski, R., et al., “Actions of Vitamin D3Analogs on Human Prostate Cancer Cell Lines: Comparison with 1,25-Dihydroxyvitamin D3”,Endocrinology136:20-26 (1995).
Søresen, O., et al., “Treatment of Senile Osteoporosis with 1α-Hydroxyvitamin D3”,Clin. Endocrinol.7:169S-175S (1977).
Aloia, J., et al., “Calcitriol in the Treatment of Postmenopausal Osteoporosis”,Amer. J. Med.84:401-408 (1988).
Baggiolini, E., et al., “Stereocontrolled Total Synthesis of 1α,25-Dihydroxyergocalciferol”,J. Org. Chem.,51:3098-3108 (1986).
Brewster, M., et al., “Improved Delivery through Biological Membranes. 32.1Synthesis and Biological Activity of Brain-Targeted Delivery Systems for Various Estradiol Derivatives”,J. Med. Chem.31: 244-249 (1988).
Christiansen, C., et al., “Effect of 1,25-dihydroxy-vitamin D3in Itself or Combined With Hormone Treatment In Preventing Postmenopausal Osteoporosis”,Eur. J. Clin. Invest.11: 305-309 (1981).
Counsell, R., et al., “Lipoproteins as Potential Site-Specific Delivery Systems for Diagnostic and Therapeutic Agents”,J. Med. Chem.25:1115-1120 (1982).
Davis, S., et al. “Colloidal Delivery Systems-Opportunities and Challenges”,Site-Specific Drug Delivery, (Tomlinson et al. eds.), John Wiley, New York, 93-111 (1986).
Gallagher, J. et al., “Treatment of Postmenopausal Osteoporosis with High Doses of Synthetic Calcitriol”,Ann. Int. Med.113:649-655 (1990).
Barton, D. et al., “Synthetic Uses of
Bishop Charles W.
Mazess Richard B.
Bone Care International, Inc.
Chan Christina
Hartwig Gregory J.
Huynh Phuong
Michael & Best & Friedrich LLP
LandOfFree
Targeted therapeutic delivery of vitamin D compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Targeted therapeutic delivery of vitamin D compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeted therapeutic delivery of vitamin D compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3505388